Stress-Induced Degradation Profiling of Evogliptin by Stability-Indicating Reversed-Phase High-Performance Liquid Chromatography and Liquid Chromatography-Mass Spectrometry.
Abstract
A stability-indicating reversed-phase high-performance liquid chromatographic method was developed and validated for quantitative determination of evogliptin in bulk drug substance and a marketed tablet formulation, followed by supporting liquid chromatography-mass spectrometry investigation of selected stress-associated components. Separation was achieved on an Eclipse XDB C8 column (250 × 4.6 mm, 5 μm) using acetonitrile and 0.1% formic acid in water (80:20, v/v) at 1.0 mL/min, with photodiode-array detection at 268 nm and a 10 min run time. The method was linear over 10-60 μg/mL (R2 = 0.9993), with repeatability and intermediate precision below 2%. Mean recoveries ranged from 99.657 to 100.555%. The marketed tablet assay was 100.161 ± 0.333%. Forced-degradation studies showed parent-drug response losses of 10.90%, 23.61%, and 9.08% under acidic hydrolysis, alkaline hydrolysis, and oxidative stress conditions, respectively. Thermal and photolytic solid-state exposure produced only 0.40% and 0.08% response loss, respectively, under the conditions investigated. Full-scan LC-MS showed ions at m/z 186.2, 363.3, and 417.4 associated with DP1, DP2, and DP3, respectively. These findings support stress association but not definitive structures, as product-ion MS/MS, accurate-mass measurements, and authentic degradation-product standards were not used. This study integrates quantitative stability-indicating chromatographic assessment with conservative mass-spectrometric investigation of selected stress-associated components.